Home
University of Bergen
The Department of Biomedicine

News archive for The Department of Biomedicine

Trial lecture and public defence: Tor-Arne Hegvik (29.01.2019)
The candidate will give a trial lecture and defend his doctoral thesis with the title: “Attention-deficit/hyperactivity disorder and autoimmune diseases: etiological relationships and therapeutic possibilities”
Slide scanner picture
New microscope ready for use (22.01.2019)
Early Stage Researcher Seminar - Tor-Arne Hegvik (21.01.2019)
Attention-deficit/hyperactivity disorder and autoimmune diseases: etiological relationships and therapeutic possibilities
Cancer DNA
Nature: A new tool to classify tumors of the central nervous system (15.01.2019)
There are over 100 tumor types only in the central nervous system. The Translational Cancer Research Group at the Department of Biomedicine provided data and material for a new diagnostic tool that will make it easier for cancer researchers to see the difference.
Szigetvari et al
The Quaternary Structure of Human Tyrosine Hydroxylase (14.01.2019)
The enzyme tyrosine hydroxylase is essential for life. Neurological, psychiatric and cardiovascular disorders occur when its catalytic function is impaired. Researchers at the Department of Biomedicine describe how new insights into the protein might help develop new avenues for treatment.
EPIC XS
EPIC-XS: Ten Million Euro for Access to European Proteomics Facilities (11.01.2019)
Thomas Arnesen and Harald Barsnes from the Department of Biomedicine are part of a new european consortium in the field of mass spectrometry based proteomics research. The European Union has awarded 10 million Euro.
Shoes in garden
Actin Modifications: Finding the Right Shoe for Cinderella (11.01.2019)
Cinderella is a tale of being lifted from obscurity to recognition and significance. A review by young researchers at the Department of Biomedicine highlights the importance of the post-translational modifications of actin.
Mikroskopisk bilde av en nervecelle i netthinnen
Extrasynaptic glutamate receptors in the retina (12.12.2018)
The Retinal Microcircuits Research Group investigates how neurons in the retina communicate to produce vision. In their latest study, they looked outside the conventional neural circuits and found some unexpected receptor molecules in unexpected locations.
Early Stage Researcher Seminar - Md Abdul Latif (11.12.2018)
Suicide gene therapy of glioblastoma induces an immunosuppressive microenvironment.
MAG-DYNLL1 complex
A novel protein interaction in myelin (01.12.2018)
One long-standing question in myelin biochemistry was solved, as a new binding partner specific for the large isoform of MAG was identified.
ADHD
ADHD is genetic (30.11.2018)
There is a clear connection between specific genes and ADHD. This is the result of a large international study where UiB-researchers have played an important role, led by Professor Jan Haavik.
Screen in conference room CSMB 2018.
Three Scandinavian scientists invited to the third National Conference of the Chinese Society of Matrix Biology (26.11.2018)
Matrix Biology group leader and CCBIO PI Donald Gullberg recently returned from an inspiring conference in China.
Midway evaluation - Kunwar Jung KC (20.11.2018)
Midway evaluation - Jahedul Alam (20.11.2018)
Midway evaluation - Sissel Elisabeth Dyrstad (20.11.2018)
Hjernesvulstforeningen besøker Brain tumor Immunology and Therapy Group hos Instituttet for biomedisin
Patient organization collaborates with researchers to improve brain cancer therapy (19.11.2018)
The research laboratory for brain cancer immunology and therapy at the Department of Biomedicine has received the secretary general of the Brain-Tumour Society Rolf Ledal to discuss current and future research projects.
Brain Cancer
Millions to research on brain cancer (07.11.2018)
The Norwegian Cancer Society will give 4 million kroner (NOK) to research on brain cancer´s communication networks, via so-called microtubes.
Logo Hjernesvulstforeningen
Bortezomib and Temozolomide in Recurrent Glioblastoma With Unmethylated MGMT Promoter (11.10.2018)
This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent glioblastoma with unmethylated MGMT promoter treated with Bortezomib and Temozolomide in a specific schedule.

Pages